(Q35057371)

6 August 2017

1 reference

title

Overview of the main outcomes in breast-cancer prevention trials (English)

1 reference

6 August 2017

1 reference

7

1 reference

6 August 2017

J Cuzick

1

1 reference

6 August 2017

T Powles

2

1 reference

6 August 2017

U Veronesi

3

1 reference

6 August 2017

J Forbes

4

1 reference

6 August 2017

R Edwards

5

1 reference

6 August 2017

S Ashley

6

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

361

1 reference

6 August 2017

issue

9354

1 reference

6 August 2017

page(s)

296-300

1 reference

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912342-2

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912342-2

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912342-2

7 January 2021

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912342-2

7 January 2021

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912342-2

7 January 2021

Tamoxifen for breast cancer among hysterectomised women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912342-2

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912342-2

7 January 2021

Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912342-2

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912342-2

7 January 2021

10.1016/S0140-6736(03)12342-2

Identifiers

DOI

1 reference

6 August 2017

1 reference